Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
News|Articles|September 17, 2018
Aptar Pharma to Host Drug Delivery Insight Briefing at CPhI 2018
Author(s)Pharmaceutical Technology Editors
Guenter Nadler, director of Business Development at Aptar Pharma, will present an insight briefing on new drug-delivery trends in treating upper and lower respiratory tract issues on Wednesday, Oct. 9, 2018 at CPhI Worldwide.
Advertisement
Guenter Nadler, director of business development at Aptar Pharma, will present an insight briefing on new trends in treating upper and lower respiratory tract issues, including new respiratory technology platforms designed to market needs, on Tuesday, Oct. 9, 2018 in Madrid, Spain at CPhI Worldwide.
The discussion, “Portable Care for Your Respiratory Tract: Exploring New Technology Platforms,” will explore the necessity for more modern, portable treatments and offer insight into how to deliver such solutions to clients. Nadler’s briefing will take place at 12:30–1:00pm at InnoPack & P-MEC Theatre, Hall 4, stand 4F121.
As part of Aptar Pharma’s Consumer Health Care division, Nadler heads strategy and innovation for the company’s Cough & Cold business. He has 18 years of experience in drug delivery, including various technical and commercial roles.
Source:
Advertisement
Related to this article
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Advertisement
Advertisement